MIST
Milestone Pharmaceuticals Inc.
$1.32
+0.00 (+0.00%)
At close · Jul 2
Market Cap
$164.34M
Shares
124,497,980
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.32
Open$1.32
Day$1.29–1.38
52W$1.00–3.06
Avg vol 30d1.2M
Short int10.6M · 8.5% float · 8.7d
Short vol65%
Last earningsMay 13, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 13
Equibles Rating
blended score · not investment advice
Overall
Sell
Technical · trend & momentum
Sell
◦
50 / 200-day cross
no cross
−
Price vs 200-day avg
−28% below
−
Price vs 50-day avg
−13% below
◦
RSI (14)
46 · neutral
+
MACD trend
positive
◦
52-week position
16% · mid-range
Sentiment · smart money
Neutral
◦
Trend (MA cross)
50d $2 › 200d $2 — 200d above 50d
+
Institutional flow
+8% holders QoQ · +20 funds added
−
Insider flow
Net -$82.5K over 90 days · 100% sells
−
Short interest
8.52% of float · ▲ +15.4% MoM · 8.7 days cover
◦
Volume signal
Volume near normal
+
Institution breadth
85 holders — near 3-yr high, broad support
Fundamentals
Weak
−
EPS growth
−12% Y/Y
−
Free cash flow
$-49.3M
+
Balance sheet
net cash $15.9M
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
Next earnings call
Aug 12, 2026
Est · unconfirmed
· in 5 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 13, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
−28% below
Bearish
Price vs 50-day avg
−13% below
Bearish
RSI (14)
46 · neutral
Neutral
MACD trend
positive
Bullish
52-week position
16% · mid-range
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow
Accumulating
+8% holders QoQ · +20 funds added
Insider flow
Distributing
Net -$82.5K over 90 days · 100% sells
Short interest
Rising
8.52% of float · ▲ +15.4% MoM · 8.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
85 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $1
Now $1 · 16%
52-wk high $3
vs 200-day avg -28%
vs 50-day avg -13%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| commercially insured lives with coverage for CARDAMYST | 25% | through April 2026 | — |
| patients with PSVT on CARDAMYST | 560 | through April 2026 | — |
| scripts filled for CARDAMYST | 600 | through April 2026 | — |
| unique prescribers for CARDAMYST | 400 | through April 2026 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MIST
this stock
Milestone Pharmaceuticals Inc.
|
$164.34M | -34.7% | — | — | 8.5% |
|
AKTX
Akari Therapeutics Plc
|
$953.21B | -9.9% | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$470.30B | -2.0% | +22179.2% | 957.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$134.02B | +16.5% | +46.2% | 31.3 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.80B | -15.1% | +20.8% | 16.3 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MIST | +5.6% | +3.1% | -39.7% | -1.5% | -34.7% |
| SPY | +1.4% | -1.3% | +8.0% | -0.3% | +9.2% |
| vs SPY | +4.2% | +4.4% | -47.8% | -1.2% | -43.9% |